PF Products & Features GmbH Expands Its Horizons with AVVie GmbH Acquisition
On August 6, 2026, PF Products & Features GmbH (PF) made headlines with the announcement of its acquisition of AVVie GmbH. This strategic move is anticipated to significantly bolster PF's offerings in the realm of structural heart disease treatments. At the heart of this acquisition is the innovative AngelValve™ Augmentation System developed by AVVie, a company founded by renowned cardiac surgeon Professor Werner Mohl. This state-of-the-art platform aims to address critical unmet therapeutic needs in treating mitral valve diseases, providing new hope for patients who currently have limited options.
The statistics surrounding mitral valve regurgitation—a condition where blood leaks back into the left atrium of the heart—are alarming, with over 13 million individuals affected in Europe and the United States alone. Despite the prevalence of this condition, only a fraction—approximately 5%—of patients with moderate to severe forms receive treatment. As a key aspect of PF's mission, addressing this therapeutic gap is paramount, along with improving the quality of life for millions impacted by this chronic ailment.
Through this acquisition, PF aims to synergize AVVie's robust research and development capabilities with its own global expertise in product development, clinical research, regulatory affairs, manufacturing, and commercialization. This collaboration is expected to accelerate innovation and shorten the timeline for bringing new therapies to market.
Katharina Kiss, CEO of PF, emphasized the significance of the acquisition, stating, "The acquisition of AVVie reflects our steadfast commitment to developing breakthrough therapies for patients suffering from structural heart diseases. By merging AVVie's engineering excellence with PF’s extensive experience in clinical trials and regulatory processes, we establish ideal conditions for advancing the AngelValve™ platform and delivering meaningful innovations to healthcare professionals and patients worldwide. This acquisition marks another crucial step towards achieving our vision of becoming a global leader in structural heart disease therapies."
Siegfried Einhellig, COO and President of PF, also highlighted the strategic benefits of combining exceptional engineering expertise with a proven track record in medical technology development. "We are excited about the prospect of transforming this innovation into an effective therapy," he noted.
While the financial terms of the deal have not been disclosed, it is clear that this acquisition is a significant milestone for PF Products & Features GmbH, a global player in the medical technology sector for over 25 years. Headquartered in Vienna and operating in approximately 70 countries, PF has manufacturing sites across Europe, Asia, and Brazil. The company is well-known for developing innovative solutions in cardiovascular medicine.
With this acquisition, PF is set to enhance its product portfolio and leverage new technologies to address a critical health issue affecting millions. The collaboration promises not only to innovate existing treatments but also to pave the way for future advancements in heart disease therapies, aligning perfectly with the ever-evolving landscape of medical technology.
As PF Products & Features continues to solidify its position in the cardiovascular sector through strategic acquisitions and cutting-edge research, the future looks promising for patients in need of effective treatments for structural heart diseases. The AngelValve™ platform may soon play a pivotal role in transforming the therapeutic landscape, offering new hope to those battling mitral valve conditions.
The statistics surrounding mitral valve regurgitation—a condition where blood leaks back into the left atrium of the heart—are alarming, with over 13 million individuals affected in Europe and the United States alone. Despite the prevalence of this condition, only a fraction—approximately 5%—of patients with moderate to severe forms receive treatment. As a key aspect of PF's mission, addressing this therapeutic gap is paramount, along with improving the quality of life for millions impacted by this chronic ailment.
Through this acquisition, PF aims to synergize AVVie's robust research and development capabilities with its own global expertise in product development, clinical research, regulatory affairs, manufacturing, and commercialization. This collaboration is expected to accelerate innovation and shorten the timeline for bringing new therapies to market.
Katharina Kiss, CEO of PF, emphasized the significance of the acquisition, stating, "The acquisition of AVVie reflects our steadfast commitment to developing breakthrough therapies for patients suffering from structural heart diseases. By merging AVVie's engineering excellence with PF’s extensive experience in clinical trials and regulatory processes, we establish ideal conditions for advancing the AngelValve™ platform and delivering meaningful innovations to healthcare professionals and patients worldwide. This acquisition marks another crucial step towards achieving our vision of becoming a global leader in structural heart disease therapies."
Siegfried Einhellig, COO and President of PF, also highlighted the strategic benefits of combining exceptional engineering expertise with a proven track record in medical technology development. "We are excited about the prospect of transforming this innovation into an effective therapy," he noted.
While the financial terms of the deal have not been disclosed, it is clear that this acquisition is a significant milestone for PF Products & Features GmbH, a global player in the medical technology sector for over 25 years. Headquartered in Vienna and operating in approximately 70 countries, PF has manufacturing sites across Europe, Asia, and Brazil. The company is well-known for developing innovative solutions in cardiovascular medicine.
With this acquisition, PF is set to enhance its product portfolio and leverage new technologies to address a critical health issue affecting millions. The collaboration promises not only to innovate existing treatments but also to pave the way for future advancements in heart disease therapies, aligning perfectly with the ever-evolving landscape of medical technology.
As PF Products & Features continues to solidify its position in the cardiovascular sector through strategic acquisitions and cutting-edge research, the future looks promising for patients in need of effective treatments for structural heart diseases. The AngelValve™ platform may soon play a pivotal role in transforming the therapeutic landscape, offering new hope to those battling mitral valve conditions.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.